v3.22.4
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2022
Income Tax Disclosure [Abstract]  
Summary of the Domestic and Foreign Components of Income Before Income Taxes
The following is a summary of the domestic and foreign components of income before income taxes for the years ended December 31, 2022, 2021 and 2020:
Year Ended December 31,
(in thousands)202220212020
Domestic$11,216 $42,221 $31,667 
Foreign84 143 (12)
Total income before income taxes$11,300 $42,364 $31,655 
Summary of Provision (Benefit) for Income Taxes
The following is a summary of the provision (benefit) for income taxes for the years ended December 31, 2022, 2021 and 2020:
 Year Ended December 31,
(in thousands)202220212020
Current
Federal$— $— $— 
State3,710 2,200 2,061 
Foreign185 267 68 
Deferred
Federal1,238 6,604 6,076 
State(111)119 155 
Foreign22 (42)
Provision for income taxes$5,025 $9,212 $8,318 
Reconciliation Between Statutory Tax Rate and Effective Tax Rate
The following is reconciliation between the federal statutory tax rate and the Company’s effective tax rate for the years ended December 31, 2022, 2021 and 2020:
 Year Ended December 31,
 202220212020
Federal tax at statutory rate21.0 %21.0 %21.0 %
State taxes4.8 %2.3 %2.6 %
Change in valuation allowance1.0 %(0.1)%(3.5)%
Research and development credit(25.9)%(6.5)%(5.4)%
Orphan drug credit(0.9)%(0.1)%(1.3)%
Section 162(m) limitation9.4 %2.6 %1.7 %
Other tax rate changes1.7 %(0.2)%0.2 %
Uncertain tax positions24.5 %4.0 %4.7 %
Stock-based compensation5.8 %(1.8)%5.1 %
Settlements2.6 %— %— %
Other items0.5 %0.5 %1.2 %
Effective tax rate44.5 %21.7 %26.3 %
Components of Net Deferred Tax Assets and Related Valuation Allowance
The following is a summary of the components of the Company’s net deferred tax assets and the related tax valuation allowance as of December 31, 2022 and 2021.
(in thousands)December 31, 2022December 31, 2021
Deferred tax assets
Net operating loss carryforwards$13,746 $35,509 
Stock-based compensation4,930 4,846 
Accrued expenses1,469 1,409 
Allowance for returns and credit losses1,560 1,142 
Research and development and orphan drug credit carryforwards42,402 39,975 
Capitalized research and development expenses16,990 — 
Other3,798 3,081 
Total deferred tax assets84,895 85,962 
Deferred tax liabilities
Intangible assets(1,924)(1,919)
Other(1,796)(2,140)
Total deferred tax liabilities(3,720)(4,059)
Deferred tax assets, net81,175 81,903 
Less: Valuation allowance7,136 7,025 
Net deferred tax assets$74,039 $74,878 
Summary of Changes in Tax Valuation Allowance
The following is a summary of changes in the Company’s tax valuation allowance for the years ended December 31, 2022, 2021 and 2020:
(in thousands)
Balance at
Beginning
of Year
AdditionsReductions
Balance at
End of
Year
Year Ended
December 31, 2022$7,025 $111 $— $7,136 
December 31, 20217,051 — (26)7,025 
December 31, 20208,155 — (1,104)7,051 
Reconciliation of Gross Unrecognized Tax Benefits
A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:
Year Ended December 31,
(in thousands)202220212020
Unrecognized tax benefits at the beginning of the year$12,935 $11,233 $9,741 
Increases (decreases) related to prior year tax positions(75)122 (121)
Increases related to current year tax positions2,895 1,580 1,613 
Settlements(270)— — 
Unrecognized tax benefits at the end of the year$15,485 $12,935 $11,233